A 52-wk Randomised, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Metformin) Study to Evaluate the Efficacy, Safety & Tolerability of Tesaglitazar Therapy When Administered to Patients With Type 2 Diabetes.

Trial Profile

A 52-wk Randomised, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Metformin) Study to Evaluate the Efficacy, Safety & Tolerability of Tesaglitazar Therapy When Administered to Patients With Type 2 Diabetes.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Tesaglitazar (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms GALLANT-5
  • Most Recent Events

    • 30 Jun 2013 Planned number of patients changed from 580 to 775 as reported by United Kingdom Clinical Research Network record.
    • 12 Nov 2010 Status changed from completed to suspended as reported by United Kingdom Clinical Research Network record.
    • 04 Aug 2010 New source identified and integrated (United Kingdom Clinical Research Network).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top